Cipla USA Inc., a wholly owned subsidiary of Cipla Limited, has announced the immediate U.S. launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens. The product is the generic equivalent of Saxenda® (liraglutide injection).
The launch follows the Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration for generic liraglutide, secured by Cipla’s partner Orbicular Pharmaceuticals, Inc..
Under the collaboration:
Liraglutide Injection is a complex injectable peptide delivered via a multidose prefilled pen drug–device combination.
Indication:
Liraglutide is a synthetic GLP-1 analog, administered once daily by subcutaneous injection.
GLP-1 receptor agonists are among the fastest-growing therapeutic classes globally, driven by:
With this launch, Cipla becomes one of the few companies offering generic versions of both Victoza® and Saxenda® in the U.S.
“This development represents a key milestone in our peptide portfolio and strengthens our differentiated U.S. offering,” said Achin Gupta, Global CEO & MD Designate, Cipla.
He emphasized Cipla’s focus on expanding access to high-quality, affordable medicines at scale.
Marc Falkin, CEO of Cipla North America, added that Cipla’s commercial infrastructure and channel relationships position the company to ensure broad availability across the U.S.
Glucagon-like peptide-1 (GLP-1) therapies support metabolic control by:
These mechanisms underpin their growing role in weight management and metabolic care.
With the launch of generic liraglutide injection, Cipla strengthens its U.S. complex generics portfolio and expands patient access to a proven GLP-1 therapy.
As demand for obesity and metabolic treatments accelerates, this move positions Cipla as a serious generic contender in the GLP-1 space.